Comparative Pharmacology
Head-to-head clinical analysis: BUSULFAN versus BUSULFEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSULFAN versus BUSULFEX.
BUSULFAN vs BUSULFEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Busulfan is a bifunctional alkylating agent that crosslinks DNA, primarily at guanine N7 positions, leading to DNA strand breaks and inhibition of DNA replication and transcription. It is cell cycle phase-nonspecific.
Busulfan is a bifunctional alkylating agent that cross-links DNA, leading to inhibition of DNA replication and cell death.
1-4 mg/day orally for remission induction in CML; 0.8-1 mg/kg every 6 hours orally for 4 days as part of myeloablative conditioning with cyclophosphamide.
Busulfan 0.8 mg/kg IV every 6 hours for 4 days (total 16 doses) or 3.2 mg/kg IV once daily for 4 days, based on ideal body weight or actual body weight (whichever is lower).
None Documented
None Documented
Clinical Note
moderateBusulfan + Digoxin
"Busulfan may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateBusulfan + Digitoxin
"Busulfan may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateBusulfan + Deslanoside
"Busulfan may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateBusulfan + Acetyldigitoxin
"Busulfan may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 2.5 to 4 hours (mean ~2.6 hours) after oral administration; prolonged to 3-5 hours with high-dose regimens. Half-life may increase with hepatic impairment.
Terminal elimination half-life is approximately 2.5 hours (range: 1.5-4.0 hours) in adults. In children, half-life is shorter (~1.4 hours). Clinically, this supports high-dose, fractionated dosing regimens (e.g., every 6 hours) to maintain therapeutic levels.
Renal (10-50% unchanged), hepatic metabolism (primarily via glutathione S-transferases) with metabolites excreted in bile and urine. Fecal excretion minimal (<5%).
Primarily hepatic metabolism via conjugation with glutathione, followed by renal excretion of metabolites. Less than 2% of the parent drug is excreted unchanged in urine. Fecal excretion is negligible.
Category C
Category C
Alkylating Agent
Alkylating Agent